Dystrophia myotonia type 1 (DM1; Steinert's disease; myotonic dystrophy) is an autosomal dominant disorder due to a large CTG expansion in the 3 0 -untranslated region (UTR) of the DM protein kinase (DMPK) gene. Transcription of this gene yields a long CUGn-containing mutant (mut) RNA, in which clinical disease is associated with repeats of n ¼ 100 -5000. Phenomenologically, the expression of mut RNA is correlated with the morphologic observation of ribonucleoprotein precipitates ('foci') in the nuclei of DMPK-expressing cells. The prevailing view is that the identification of proteins in these foci is the sine qua non of protein -mut RNA interactions. In this viewpoint, I contend that this is an unwarranted inference that falls short in explaining published data. A new model of mut RNA -protein interactions is proposed with distinct binding properties for soluble and insoluble (focus) mut RNA that accommodate these data without exclusions. Keywords: mutant RNA; RNA configuration; protein binding; CUGBP; MBNL; transcription factors
Mechanisms in dystrophia myotonia
Dystrophia myotonia (DM) includes an array of seemingly unrelated clinical phenotypes, and a variety of mechanisms have been posited to account for its diverse features. The CUGn-expanded DMPK mRNA (mutant (mut) RNA) is not transported to the cytoplasm for translation but retained in the nucleus.
1,2 Early research examined the effects of the resultant haploinsufficiency of DMPK, and then that of the transcriptionally disrupted flanking genes, SIX5 and DMAHP, but all of these cis effects together did not have explanatory value for more than a minor portion of the phenotypes. 3, 4 Ensuing work then focused on trans gain-of-function effects of the mut RNA itself. Initially implicated in this group was the splicing factor CUG-binding protein (CUGBP). 5, 6 In the presence of mut RNA, CUGBP was bound into a ribonucleoprotein (RNP) complex that delayed its normally rapid catabolism, leading to CUGBP accumulation and hyperactivity in the nucleus. This hyperactivity led to improper mRNA splicing of various RNAs and aberrent isoforms of the CIC-1 chloride channel molecules that were implicated in myotonia. [7] [8] [9] [10] splicing and cardiac and skeletal muscle abnormalities were recapitulated in transgenic models of CUGBP overexpression. 11 Subsequently, another RNA-splicing protein, muscleblind-like (MBNL), was shown to be bound by mut RNA, but it was inhibited in its activity. 12 As MBNL works contrarily to CUGBP, its suppression provided similar effects as CUGBP overexpression, creating analogous splicing abnormalities. Correspondingly, MBNL knockout mice had features of eye, muscle and splicing abnormalities seen in DM. 13 MBNL was suggested by RNAi experiments to be the more central factor in splicing abnormalities for one mRNA species in affected myocytes, 14 but other mRNAs were not studied nor were other tissues.
More recently, a further potential mechanism was described in DM-affected cells. In this, mut RNA binds and sequesters nuclear transcription factors (TFs), leading to the depletion of TFs ('leaching') from active
Foci: cause or corollary?
There has been a prevailing notion that (i) mut RNA in DM cells exists solely as foci. A less restrictive model would be that (ii) mut RNA in foci is representative of all mut RNA for protein binding -if it is shown that mut RNA also exists outside the foci. Model (i) 'foci mut RNA being all mut RNA' can be seen to be a special case of model (ii) 'foci mut RNA representing all mut RNA'. For the purpose of this essay, the consequences are the same for either representation (i and ii) of mut RNA properties, and we group them collectively under model A.
The identification of proteins in foci became the de facto sine qua non of protein -mut RNA interactions: it has been variously stated that binding of CUGBP to mut RNA in vivo is controversial because experiments do not detect CUGBP in foci, 14 CUGBP has been questioned for having any interaction with DMPK in vivo, 19 CUGBP binding by mut RNA was unlikely to be responsible for splicing defects, 22 in general challenging any role of CUGBP binding in DM1 pathophysiology. 19 Similarly, once TFs were shown not to be in foci, the in vivo data on binding of TFs by mut RNA and leaching from chromatin, on depressed mRNA and proteins in DM1 cells and on their normalization with select TF restorations were discounted as an indirect evidence. 22 The foci-causal view is summarized as follows:
'evidence suggests that RNA inclusions (foci) are directly involved in disease pathogenesis, through a mechanism that involves sequestration of muscleblind proteins and misregulation of alternative splicing'. 22 An alternate view to the above is that it is mut RNA binding rather than focus formation that is the important feature in DM, irrespective of the fraction of a protein that is bound into mut RNA foci. In this view, the appearance of foci may reflect the disease but is not causative or essential to the disease process. It was conceded earlier that there could be a non-focus form of mut RNA with a contributing role in DM, 21 and the role of morphologic foci in splicing dysregulation has been questioned by others. 24 Yet even when high levels of short CUGn-containing RNAs yielded DM-like findings without foci, 25 attention remained entirely on unknown MBNL interactions in this experiment 26 with no mention of the alternative possibility of contributions from CUGBP -mut RNA binding. In this viewpoint, I propose that foci are only one of the different forms of mut RNA in the cells and that the different forms have distinct binding properties. The evidence derives from published data on CUGBP -mut RNA interactions, with more limited corroborating data on TF binding. From this, a new and testable model evolves that more broadly accommodates the data and resolves apparent discrepancies.
The example of CUGBP
Available data on CUGBP -mut RNA binding are detailed in the following and summarized in Table 1 . We separately consider biochemical and morphologic data and distinguish whether they are derived in vivo or in vitro.
Biochemical studies
In vivo By a number of in vivo biochemical tests (using intact cells), CUGBP binds selectively to the CUGn expansions in mut RNA (Table 1) . Extracts from DM (but not wild-type) cells showed increased molecular weight (MW) for CUGBP on size-exclusion chromatography, in accord with its binding to a large RNA (Figure 1a) . 8 As mentioned above under Mechanisms, binding by mut RNA in vivo has the effect of prolonging the normally short half-life of CUGBP. 8 This longer survival translates into higher in vivo concentrations of CUGBP 8, 25, 29 and increased net splicing activity that recapitulates the splice variants seen in DM cells. 7 -11,25 It is clinically observed that disease severity parallels increased repeat length. Phillips et al 7 similarly showed that in- This observation leads to a further -pharmacodynamicargument that has not previously been considered. By first principles of interacting decaying systems, when a short-lived component binds to a longer lived, the ratio of increase in steady-state concentration of the first approaches the ratio of the half-lives. 30 That is, with the normal CUGBP half-life of 3 h 8 and mut RNA half-life of B15 h (same as wt), 2 the half-life ratio of 5 directly predicts up to fivefold increase in steady-state CUGBP levels due to complexing. Up to fivefold increase in CUGBP levels is what was observed in the quantitation of Figure 1c A further consequence of the pharmacodynamic argument is that protein levels at steady state cannot increase by more than the excess of the second and longer surviving component to which it is bound. 30 That is, an observed fivefold increase in CUGBP levels in DM tissue requires at least a fivefold excess in available mut RNA-binding sites -and the excess could be much greater. It also implies that CUGBP is virtually totally bound, as supported by the observations of Figure 1a . Correspondingly, CAGn expansions do not bind CUGBP, do not lead to elevated CUGBP levels and do not induce splicing abnormalities, although CAGn binds and sequesters MBNL into foci. 24 This indicates that CUGBP elevation is a secondary consequence neither of focus formation nor of MBNL depletion, consistent with the direct binding role of CUGn in prolonging CUGBP survival and increasing cellular levels. (Figure 1d ). This in vitro observation with 'RNA-free' CUGBP then parallels the in vivo length effects of Figure 1c .
In vitro

d
Morphological studies In vitro Earlier in vitro biochemical tests had shown that purified CUGn forms double-stranded (duplex) hairpins in solution. 33, 34 In vitro examinations by electron microscopy (EM) confirmed duplex regions to which added purified CUGBP did not bind, attaching only to the CUGn singlestranded tails at hairpin bases. 31 As longer CUGn would be absorbed into longer CUG:GUC hairpins, this observation has been interpreted to imply that the CUGn length effect noted clinically could not be explained by CUGn binding of CUGBP: there would always be a constant molar binding ratio. However, this interpretation from in vitro data is inconsistent with in vivo observations of Figure 1c , where a length effect is evident. This apparent conflict is plausibly resolved by the following considerations. First, the protein used in these EM tests was the same 'RNA-blocked' CUGBP (see above) that failed to show increased binding with increased CUGn length in vitro, 31 in contrast to the 'RNA-free' CUGBP that bound more to longer CUGn (Figure 1d) . 27 With the small In vivo Finally, and the key reason for the current proposal, in vivo morphologic studies showed that CUGBP does not colocalize with mut RNA in foci ( Figure 2 ).
21,22
Instead, CUGBP is dispersed throughout the nucleoplasm.
Following the evidence that all or most CUGBP is bound into a mut RNA complex in vivo ( Figure 1a , Table 1 ), observation of dispersed CUGBP implies that mut RNA, bound to CUGBP, is also dispersed in the nucleoplasm, that is, in a soluble, or at least microdisperse form -in addition to the fraction that is in foci. This inference is corroborated by analogous observations of TF binding: mut RNA that leaches Sp1 and RAR out of chromatin and into mut RNA-containing RNP 15 is revealed by TF staining in vivo as a dispersed complex in the nucleoplasm of DM-affected cells. 22 The weight of diverse biochemical and functional measures seems to support a biologically relevant association of CUGBP and TFs with mut RNA. Under the currently prevailing concepts, however, these factors have been undervalued as potential contributors to DM pathology.
Logic for a new model
This situation has been suggested to confront us with a disjunction between the biochemical binding data for CUGBP and TFs and their morphologic non-observation in foci. Yet both the biochemical and morphological data were separately judged as credible by peer-reviewers when they were published. To then downgrade the biochemical data, however, it is fair to ask: what logic impels us to their exclusion? Model A provides one such logic, with the key component highlighted. From model A:
(
Yet, if we reconsider the above formulation to modify the last statement (4) to an alternative hypothesis, another, less restrictive model (model B) emerges:
(1) Proteins are bound to mut RNA. We note that there is nothing in the logic of statements 1 -3 that is inherently in conflict with the new statement 4. However, this formulation, inescapably implying (7), begs the question: How can a soluble form of mutant RNA differ from a focus form? The RNAs are the same chemically.
A new model of mut RNA conformation and binding Here, I propose a model (B) that is consistent with the broader range of data, in which focus localization is sufficient, but not necessary for, a conclusion of protein binding by mut RNA.
In vitro, CUGn self-pairs as CUG:GUC, in which nonstandard U:U pairing has been shown to be permissive, creating 'metastable slippery hairpins'. 33 In vivo, RNA, including mut RNA, exists not as naked RNA but in complex with RNA-binding proteins as RNP with distinct properties. 15, 37, 38 Proteins that bind to ss RNA (we call 'class I') will tend to melt out ds duplex regions and favor a linear single-stranded state. CUGBP would be a class I protein, as would influenza ssRNA-binding protein, 39 in parallel with class I proteins first described for DNA. There (Figure 3a) . When MBNL levels are suppressed experimentally by RNAi, foci are reduced 14 and, because the quantity of mut RNA is the same, a substantial fraction of mut RNA therefore cannot but be in the non-focus (ie, soluble or disperse) fraction. This, per se, is evidence that focus and soluble mut RNA fractions can coexist in vivo. This result indicates that mut RNA is soluble in vivo in the absence of MBNL and that the complex of MBNL with mut RNA to stabilize ds regions renders a portion of the RNA insoluble.
g Inasmuch as both ss and ds nucleic acids are soluble (including purified CUGn), it is some property of the MBNL protein -RNA complex, perhaps involving charge neutralization and/or secondary protein -protein interactions, that renders mut RNA non-soluble to result in foci. In general, ds nucleic acids have lower solubility and more readily aggregate or precipitate in complex. 42 Where RNAs are MBNL bound but interspersed with ss or unbound ds domains, these complexes are predicted not to be in foci, but to remain soluble (or microdisperse), as recently shown with the troponin T pre-mRNA -MBNL complex. 26 A dense coalescence of protein onto the RNA is likely to be the mechanism for insolubility, as will occur for MBNL on extended CUG hairpins 26 ( Figure 3a , right).
The act of stabilizing hairpins by MBNL binding is predictably a cooperative phenomenon (Figure 3b ). This means that binding of each MBNL clamps the adjacent duplex to facilitate the binding of the next MBNL, with each bound MBNL rendering the duplex more stable, closing like a zipper. Our supposition of cooperative binding is buttressed by the recent demonstration of MBNL homotypic protein -protein interactions on the CUGn duplex. 26 Logically, this zippering process also progressively excludes CUGBP that is bound to the ss CUGn, leading ultimately to essentially pure cocrystals of mut RNA and MBNL, in direct analogy to the exclusion of impurities during a crystallization. This mechanism could explain why CUGBP is absent from foci ( Figure 2 ) yet highly bound to non-focus soluble mut RNA ( Figure 1a) .
As foci form, the deeper portion is removed from the exchangeable solution. This is seen in photobleaching experiments by the large immobile fraction of MBNL in foci, h whereas MBNL not in foci is fully mobile and recovers fluorescence completely. 24 In turn, as MBNL coprecipitates with mut RNA into insoluble foci, the residual free MBNL in the solution is progressively depleted (Figure 3b ) and thus less able to exclude CUGBP from mut RNA binding. With CUGBP now predominating in solution, the remaining binding of mut RNA to CUGBP results in a soluble mut RNA form that is substantially single stranded. Other data suggest that not all MBNL is concentrated into DM foci, with up to 30 -40% dispersed in nucleoplasm. 22, 43 In this case, non-focus MBNL at depleted concentrations may also be bound to mut RNA that is still soluble, that is, mixed ds/ss in configuration as discussed above, to which CUGBP is concurrently bound. Mut RNA with accessible ss sequence binds and protects CUGBP from its normally rapid catabolism, prolonging CUGBP survival and accumulating to high levels. 8 As a still-active soluble form in complex, bound CUGBP mediates splicing to higher net activity. i,j In contrast, binding of MBNL by mut RNA in ds form suppresses its splicing activity by active site blockade or by its sequestration into insoluble foci, which removes it from solution. k CUGBP binding occurs only after MBNL is essentially fully absorbed into complex, with the extent of CUGBP binding, prolongation of survival and increased cellular levels being dictated by the excess of mut RNA-binding sites. This is represented conceptually in Figure 3c . Longer mut RNAs will have more CUGBP-binding sites after MBNL saturation. If MBNL is always fully bound first due to its higher avidity complex, then it is likely that it is this variable binding of CUGBP that mediates the length effect of CUGn in DM1 through the resulting progressive increase in CUGBP levels. For example, in Figure 3c with fixed MBNL ¼ 1 and a mut RNA ¼ 0, CUGBP ¼ 1 (normal); for mut RNA ¼ 2, CUGBP ¼ 3; and for mut RNA ¼ 4, CUGBP ¼ 5. This parallels observations in Figure 1c , with longer RNAs supplying more moles of mut RNA-binding sites. By extension, the binding of TFs to mut RNA 15 would occur in the same sequence and at the same time as CUGBP: after the MBNL absorption into mut RNA is complete, the residual soluble mut RNA binds TFs, which in turn leads to TF leaching from chromatin and decreased transcription of selected genes.
Explanatory value
The key features of the revised model are (i) the presence of a second, non-focus form of mut RNA and (ii) distinct characteristics of protein binding for the two forms. The focus form is mainly a duplex of mutant RNA bound with MBNL and other class II proteins that excludes CUGBP and TFs, whereas the soluble form is substantially single stranded, with binding of CUGBP, TFs and other class I proteins. This new model is compatible with a number of observations on which the more restrictive model A fails (Table 2) . (1) Until now, the observation that CUG5 overexpression caused DM was considered to pose a potential 'conundrum'. 25 However, the data can be understood under model B as follows: CUGBP binds short ss CUGn RNAs. 5 The large overexpression of CUG5 provides excess binding sites to compete with endogenous small 'blocking' RNAs 27 to absorb all of the CUGBP, delaying CUGBP catabolism to result in increased in vivo concentrations with CUGBP hyperactivity and increased splicing. As CUG5 RNA is too short to form ds hairpins, 33 there is no competing type II protein (MBNL) binding or focus formation and all binding is therefore ss (Figure 3a -left) (for caveat, see note l). (2) Also of interest in these CUG5 experiments is the absence of CUGBP elevation or splicing abnormalities in the heart muscle. This is understood by model B as follows. The CUG5 RNA transgene was much less expressed in the heart than in the skeletal muscle (three-to fivefold induced in cardiac vs 10-to 20-fold in skeletal 25 ). In addition, the baseline levels of CUGBP are much higher in the heart, and therefore requiring more RNA binding to increase CUGBP levels. This is seen from Figure 3c : for skeletal muscle, if the overexpressed CUG5 is equivalent to level 3 on the mut RNA scale with a starting level CUGBP ¼ 1 and MBNL ¼ 0 (for no 'protection' from MBNL), CUGBP increases from 1 to 4. In the case of heart, with CUGBP ¼ 3 at baseline ( Figure 3, In summary, model B for mut RNA -protein interactions is seen to have a broad explanatory value for DMassociated phenomena.
Future directions
Model B is a hypothesis. I believe that it has merits over the until-now prevailing model A, but tests will be important to contrast their elements. Several predictions of the new model are testable, as outlined in the following.
(1) What is the proportion of mut RNA in foci (insoluble) vs that not in foci (soluble)? This has not been measured; indeed, the coexistence of a soluble form of mut RNA in DM1 has not formally been acknowledged. The actual balance of these forms in a given tissue will depend upon the particular stoichiometries of the interacting and competing chemical components in that tissue. Although the issue of detection of soluble mut RNA vs background is not trivial m , it should be doable in expert hands with current imaging and molecular techniques. (2) What is the proportion of CUGBP in complex in DM?
From studies of Timchenko 8 cited above (Figure 1a ), nearly all of it is, and pharmacodynamic considerations indicate that it should be. The same experiments with nuclear fractions and added controls for cross-contamination to rule out post-extraction association 28 Figure 3c ); in the single relevant report, CUGBP was not measured. 
Conclusion
This proposal aims to reconcile several aspects of DM pathobiology not satisfactorily explained by current concepts. These concepts have centered around the observation of foci and an inference that proteins should be found in such foci to be considered mut RNA bound. As CUGBP and TFs do not colocalize with foci, there has been a disposition to exclude roles for CUGBP and TF binding in DM pathology. I present evidence for the existence of mut RNA in a non-focus, soluble fraction in vivo that selectively binds CUGBP and, by extension, nuclear TFs as well. I describe a model that accommodates these data, and experiments are proposed for its test. With this, the three major models of trans dominant effects from mut RNA binding should be assessed, without prejudgment, to sort out the relative contribution of mut RNA-mediated biochemical events for the individual genes and tissues affected, while remaining open to what other mediators may yet be discovered. Plausibly, one gene that is critical in one tissue may be more affected by one mechanism, and another gene in another tissue more affected by a different mechanism.
